BLOOD neurofilament light emerged as a promising biomarker for measuring treatment response in neurodegenerative disease trials, offering a potential innovation that could streamline future drug development and improve evaluation of emerging therapies. A new scoping review suggests that blood neurofilament light may offer one such opportunity, with growing evidence supporting its use as a surrogate endpoint in clinical trials. Blood Biomarker Reflected Disease Activity Across Multiple ConditionsThe review examined studies published between 2013 and 2024 that evaluated serum or plasma neurofilament light as an endpoint in interventional clinical trials. Validation Needed Before Routine Trial AdoptionThe authors concluded that blood neurofilament light has considerable potential to modernise neurological clinical trials by serving as a surrogate endpoint, particularly in disorders characterised by active neuroaxonal injury. Use of blood-based neurofilament light chain as an endpoint in clinical trials of neurodegenerative conditions: a scoping review.